...
首页> 外文期刊>Journal of medical screening >High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme
【24h】

High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme

机译:在NHS肠癌筛查计划中,粪便潜血试验呈阳性后,通过结肠镜检查检出的结直肠肿瘤增高

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objectives The UK National Health Service Bowel Cancer Screening Programme (BCSP) is based on a strategy of biennial faecal occult blood (FOB) testing. Positive results are classified as ‘abnormal’ or ‘weak positive’ based on the number of positive windows per kit or need for repeat testing. Colonoscopy is offered to both groups. We evaluate the relationship between FOB test positivity and clinical outcome in the BCSP. Setting The South of Tyne and Tees (UK) Bowel Cancer Screening Centres. Methods Data were collected prospectively on all individuals who were offered FOB testing and colonoscopy between February 2007 and February 2009. Univariable and multivariable analyses were performed to investigate the relationship between FOB test positivity and clinical outcome. Results Following FOB testing, 1524 individuals underwent colonoscopy, 1259 (83%) after a ‘weak positive’ and 265 (17%) an ‘abnormal’ result. Cancer was detected in 180 (11.8%) and adenomas in 758 (49.7%). Individuals with an ‘abnormal’ result were more likely to have cancer or be ‘high risk’ for the development of future adenomas (110/265, 41.5%) than those with ‘weak positive’ results, (236/1259, 18.7%, P < 0.0001). Those with Dukes stage B, C or D cancers or cancers proximal to the splenic flexure were more likely to have an ‘abnormal’ result. Conclusions The majority of colonoscopies were performed following ‘weak positive’ FOB results. Those with an ‘abnormal’ result were more likely to be diagnosed with cancer. The high yield of pathology in both the ‘abnormal’ and ‘weak positive’ groups justifies the need for colonoscopy in both.
机译:目标英国国家卫生服务局肠癌筛查计划(BCSP)基于两年一次的粪便潜血(FOB)测试策略。根据每个套件的阳性窗数或需要重复测试,阳性结果分为“异常”或“弱阳性”。两组均提供结肠镜检查。我们评估了BCSP中FOB测试阳性与临床结果之间的关系。在泰恩河和提斯(英国)肠癌筛查中心的南部设置。方法前瞻性收集2007年2月至2009年2月间接受FOB检测和结肠镜检查的所有患者的数据。进行单变量和多变量分析以研究FOB检测阳性与临床结果之间的关系。结果FOB测试后,有1524人接受了结肠镜检查,“弱阳性”后接受了1259(83 %),“异常”后接受了265(17 %)。在180(11.8%)的癌症和758(49.7 %)的腺瘤中检测到癌症。结果为“异常”的个体比那些结果为“弱阳性”的个体(236 / 1259,18.7 )更有可能患癌或对未来腺瘤的发展具有“高风险”(110 / 265,41.5%)。 %,P <0.0001)。患有Dukes阶段B,C或D癌症或邻近脾弯曲的癌症的患者更有可能产生“异常”结果。结论大多数结肠镜检查是在FOB结果“弱阳性”后进行的。结果“异常”的人更有可能被诊断出患有癌症。 “异常”和“弱阳性”组的病理学检查率很高,这说明两者均需要进行结肠镜检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号